Needham & Company LLC reiterated their buy rating on shares of Immunocore (NASDAQ:IMCR - Free Report) in a research note released on Wednesday,Benzinga reports. They currently have a $71.00 price objective on the stock.
Several other equities research analysts have also recently weighed in on IMCR. HC Wainwright restated a "buy" rating and set a $100.00 target price on shares of Immunocore in a research note on Wednesday. Morgan Stanley restated an "equal weight" rating and set a $35.00 target price on shares of Immunocore in a research note on Friday, March 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Immunocore has a consensus rating of "Moderate Buy" and a consensus target price of $65.64.
Get Our Latest Stock Report on IMCR
Immunocore Price Performance
Shares of IMCR stock traded up $0.53 during trading on Wednesday, hitting $28.80. The company had a trading volume of 345,561 shares, compared to its average volume of 431,489. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The firm has a market capitalization of $1.44 billion, a P/E ratio of -30.32 and a beta of 0.79. The stock's 50-day moving average price is $30.08 and its 200 day moving average price is $31.38. Immunocore has a one year low of $27.19 and a one year high of $66.00.
Institutional Trading of Immunocore
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Jefferies Financial Group Inc. acquired a new stake in Immunocore in the fourth quarter valued at $4,868,000. GF Fund Management CO. LTD. acquired a new stake in Immunocore in the fourth quarter valued at $25,000. Woodline Partners LP increased its holdings in Immunocore by 19.4% in the fourth quarter. Woodline Partners LP now owns 328,059 shares of the company's stock valued at $9,678,000 after purchasing an additional 53,378 shares during the period. Tang Capital Management LLC increased its holdings in Immunocore by 40.7% in the fourth quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company's stock valued at $45,890,000 after purchasing an additional 450,000 shares during the period. Finally, Tema Etfs LLC acquired a new stake in Immunocore in the fourth quarter valued at $330,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.
Immunocore Company Profile
(
Get Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Recommended Stories
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
